NCT04346225View on ClinicalTrials.gov

Magnetic Resonance Imaging (MRI) With Hyperpolarized Pyruvate (13C) as Diagnostic Tool in Advanced Prostate Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

July 16, 2020

Primary Completion Date

December 31, 2025

Study Completion Date

November 30, 2026

Conditions
Prostate CancerAdvanced Prostate Carcinoma
Interventions
DRUG

Hyperpolarized C13

Given by intravenous injection. When receiving two HP 13C pyruvate injections, the injections will be separated by a period of 15-60 minutes

PROCEDURE

Magnetic Resonance Imaging (MRI)

Magnetic resonance imaging (MRI) is a medical imaging technique that uses a magnetic field and computer-generated radio waves to create detailed images of the organs and tissues in your body

Trial Locations (1)

94143

RECRUITING

University of California, San Francisco, San Francisco

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

National Institute for Biomedical Imaging and Bioengineering (NIBIB)

NIH

lead

Ivan de Kouchkovsky, MD

OTHER